Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma-Reference-Cited by-同舟云学术

Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma

Published:2015-10-13 Issue:6 Volume:76 Page:1259-1265
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Galsky Matthew D.,Hahn Noah M.,Wong Bryan,Lee Karen M.,Argiriadi Pamela,Albany Costantine,Gimpel-Tetra Kiev,Lowe Nancy,Shahin Mohamed,Patel Vaibhav,Tsao Che-Kai,Oh William K.

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-015-2884-7.pdf

Reference32 articles.

1. Bellmunt J, von der Maase H, Mead GM et al (2012) Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J Clin Oncol 30(10):1107–1113. doi: 10.1200/JCO.2011.38.6979

2. Sternberg CN, de Mulder P, Schornagel JH et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42(1):50–54

3. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ (2010) Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 11(9):861–870. doi: 10.1016/S1470-2045(10)70086-3

4. Bellmunt J, Theodore C, Demkov T et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27(27):4454–4461

5. Galsky MD, Chowdhury S, Bellmunt J et al (2013) Treatment patterns and outcomes in “real world” patients (pts) with metastatic urothelial cancer (UC). ASCO Meet Abstr 31((15_suppl)):4525

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CircRNA 001418 Promoted Cell Growth and Metastasis of Bladder Carcinoma via EphA2 by miR-1297;Current Molecular Pharmacology;2020-12-31

2. Inhibition of Human Topoisomerase II by N ,N ,N -Trimethylethanammonium Iodide Alkylcarbazole Derivatives;ChemMedChem;2018-11-30

3. Synthesis of carbazole derivatives containing chalcone analogs as non-intercalative topoisomerase II catalytic inhibitors and apoptosis inducers;European Journal of Medicinal Chemistry;2018-02

4. N-thioalkylcarbazoles derivatives as new anti-proliferative agents: synthesis, characterisation and molecular mechanism evaluation;Journal of Enzyme Inhibition and Medicinal Chemistry;2018-01-01

5. Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival;Türk Üroloji Dergisi/Turkish Journal of Urology;2017-08-16